Earnings Releases·Nov 10, 2026, 4:06 PM ET

INOVIO — Third Quarter 2026 Earnings Summary

Net loss widened to $49.2 million ($0.50 per share) from $45.5 million ($0.87 per share) in the prior year period, driven primarily by a $26.9 million non-cash loss on warrant liabilities; however, total operating expenses decreased to $19.8 million as R&D spending fell to $10.6 million.
VOCERYQ received accelerated FDA approval on October 30, 2026, for Recurrent Respiratory Papillomatosis (RRP), with commercial launch anticipated in Q1 2027 and first-year inventory capacity secured.
Cash runway extends into late Q4 2027, supported by $48.4 million in existing resources and $80.5 million in net proceeds from the November 2026 public offering, though stockholders' equity turned negative to $(33.9) million.
Strategic milestones include a planned European marketing authorization submission by end-2026, a draft confirmatory study protocol submission to the FDA by year-end, and engagement of Syneos Health for commercial field deployment.
Revenue from collaborative arrangements reached $298,901 in Q3 2026 (vs. $0 prior year), with deferred revenue recorded at $651,505, while VOCERYQ sales contributions are excluded from current cash runway projections.